z-logo
Premium
Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy
Author(s) -
Lowe Kevin,
Novak Iona,
Cusick Anne
Publication year - 2007
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/j.1469-8749.2007.00823.x
Subject(s) - cerebral palsy , botulinum toxin , physical medicine and rehabilitation , medicine , movement disorders , lower limb , anesthesia , surgery , disease
The efficacy of repeated botulinum toxin A (BTX‐A) injections in two and three dose regimes, together with occupational therapy, on upper limb movement and function, was studied using an evaluator blinded, randomized, controlled two‐group trial. Forty‐two children (31 males, 11 females; range 2–8y, mean 4y [SD 1y 7mo]) with hemiplegic cerebral palsy (Gross Motor Function Classification System Level I) longitudinally participated for 30 months, with the first 6 months reported earlier (Lowe et al. 2006). The BTX‐A group ( n =21) received three injections (0, 6, and 18mo), while the delayed group had two (6 and 18mo; dose 0.5‐2.1 units/kg, mean 1.5 [SD 0.18]; dilution 100 units/0.5ml). At 30 months, no difference existed between groups on any standardized measures. First and second injections showed significant treatment effect sizes, on Quality of Upper Extremity Skills Test (5.5 p =0.01: 4.5 p =0.03); parent Goal Attainment Scaling (GAS; 3.5 p =0.02: 3.9 p =0.01; therapist GAS 7.8 p =0.00: 4.0 p =0.03); Canadian Occupational Performance Measure (performance 0.4 p =0.05: 0.4 p =0.02; satisfaction 0.4 p =0.05: 0.37 p =0.08); and Pediatric Evaluation of Disability Inventory functional skills (1.8 p =0.00: 2.3 p =0.04). BTX‐A was not linked to adverse events, suggesting repeated upper limb injections in children with hemiplegia receiving occupational therapy were safe and effective for improvement of movement and function.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here